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Neutrophils are short-lived cells that play important
roles in both health and disease. Neutrophils and
monocytes originate from the granulocyte monocyte
progenitor (GMP) in bone marrow; however, unipo-
tent neutrophil progenitors are not well defined.
Here, we use cytometry by time of flight (CyTOF)
and single-cell RNA sequencing (scRNA-seq) meth-
odologies to identify a committed unipotent early-
stage neutrophil progenitor (NeP) in adult mouse
bone marrow. Importantly, we found a similar unipo-
tent NeP (hNeP) in human bone marrow. Both NeP
and hNeP generate only neutrophils. NeP and hNeP
both significantly increase tumor growth when trans-
ferred into murine cancer models, including a hu-
manized mouse model. hNeP are present in the
blood of treatment-naive melanoma patients but
not of healthy subjects. hNeP can be readily identi-
fied by flow cytometry and could be used as a
biomarker for early cancer discovery. Understanding
the biology of hNeP should allow the development of
new therapeutic targets for neutrophil-related dis-
eases, including cancer.
INTRODUCTION
Neutrophils are themostabundantpopulationof circulatingblood
leukocytes. With many emerging studies suggesting critical roles
of neutrophils in chronic inflammatorydiseases, includingcancer,
a complete understanding of neutrophil development is impera-
tive (Huang et al., 2016; Sagiv et al., 2015; Soehnlein et al.,
2017; Summers et al., 2010). Neutrophils originate in the bone
marrow (BM). In murine BM, LinCD117 (c-kit)+ (LK) cells include
LinCD117+Ly6A/E (Sca1)+CD127 (LSK) cells that give rise to all
hematopoietic cells, LinCD117loLy6A/E+CD127+ cells that
contain the common lymphoid progenitor (CLP) that give rise to
all lymphoid lineages, and Lin CD117+Ly6A/E that selectivelyCell Re
This is an open access article under the CC BY-Ngenerate onlymyeloid lineages (Akashi et al., 2000). In this classic
hematopoietic paradigm, the LinCD117+ Ly6A/E population is
divided into commonmyeloid progenitor (CMP), megakaryocyte-
erythroidprogenitor (MEP), andgranulocytemonocyteprogenitor
(GMP) by differential expression of surface markers CD16/32
(FcRgIII/II) and CD34 (Akashi et al., 2000). CMPs are the multipo-
tent progenitors for MEP and GMP, whereas GMP have lost
erythroid potency and thus are restricted to generate granulocyte
and monocyte lineages (Manz et al., 2002).
High-dimensional mass cytometry (also known as cytometry
by time of flight [CyTOF]) has become a powerful tool to investi-
gate the hematopoietic system (Becher et al., 2014; Bendall
et al., 2011; Samusik et al., 2016). Notably, with the development
of multi-channel flow cytometry, mass cytometry and single-cell
RNA sequencing (scRNA-seq), new markers have allowed the
discovery of several new hematopoietic progenitors, including
a CD41+ megakaryocyte progenitor (MkP), a Ter119+ erythroid
precursor (Pro Ery) (Pronk et al., 2007), and the Ly6C+ committed
monocyte progenitor (cMoP) (Hettinger et al., 2013). The hetero-
geneity of GMP has been suggested in many studies. In mouse,
single-cell analysis of gene expression patterns revealed that
GMP already have restricted lineage potential toward mono-
cytes or neutrophils (Buenrostro et al., 2018; Olsson et al.,
2016). Gene expression analysis of CMP and GMP at the single-
cell level showed heterogeneity in these progenitors (Paul et al.,
2015), suggesting that classification of these subsets using
solely CD34 and CD16/32 was not sufficient. In agreement
with gene expression analysis, additional heterogeneity has
been discovered in Lin CD117+ Ly6A/E cells with the use of
additional surface markers. For example, CD105, CD150,
CD41, and CD71 divide Lin CD117+ Ly6A/E cells into pre-
MegE, preCFU-E, CFU-E, MkP, preGM, GMP, and Pro Ery
(Pronk et al., 2007). CX3CR1+ CD115+ CD135+ monocyte/DC
progenitors (MDP) were also found to partially overlap with the
classic CMP/GMP (Auffray et al., 2009). GMP heterogeneity
has also been suggested in humans (Buenrostro et al., 2018)
with similar developmental-staged transcriptional factors (such
as IRF8) in mouse (Olsson et al., 2016). Comparable with GMP,
myeloblasts are known to have both granulocytic andmonocytic
potentials (Borregaard, 2010). The use of CD64 identified aports 24, 2329–2341, August 28, 2018 ª 2018 The Author(s). 2329
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
human CD34+CD64hi monocyte progenitor within human GMPs
(Kawamura et al., 2017).
In mouse, several monocyte progenitors (Fogg et al., 2006;
Hettinger et al., 2013; Liu et al., 2009; Satoh et al., 2017) and
granulocyte progenitors, including eosinophil progenitors (Mori
et al., 2009; Zhang et al., 2004) and basophil/mast cell progeni-
tors (Arinobu et al., 2005; Qi et al., 2013), have been identified.
Several immature neutrophil precursors have also been identi-
fied (Fiedler and Brunner, 2012; Kim et al., 2017; Satake et al.,
2012; Sturge et al., 2015; Yáñez et al., 2015). However, these
precursors are late-stage precursors with neutrophil potency
(Kim et al., 2017; Sturge et al., 2015), and several show multi-
or oligo-potency (Satake et al., 2012; Yáñez et al., 2015).
Recently, a proliferative neutrophil precursor was identified in
mouse BM that generates neutrophils after intra-BM adoptive
transfer (Evrard et al., 2018). However, the long-term potency
of this precursor was not tested. Thus, several gaps in under-
standing the complete neutrophil-lineage hierarchy from CMP
to mature neutrophils remain.
In humans, the search for a unipotent neutrophil progenitor
(hNeP) has been ongoing for decades (Bainton et al., 1971;
Elghetany et al., 2004; Pillay et al., 2010; Terstappen and Loken,
1990). Human CMP and GMP express positive levels of CD34
and CD38 andmirror themurine CMP/GMP paradigm in myeloid
cell production (Doulatov et al., 2010; Edvardsson et al., 2006;
Manz et al., 2002). A missing link in human neutrophil develop-
ment is the identification of NePs that are downstream of GMP
but upstream of short-term neutrophil precursors. Recently,
mass cytometry analysis of human BM neutrophils indicates
that human neutrophils are heterogeneous and contain a
CD117CD34CD49d+CD101 subset termed preNeu (Evrard
et al., 2018). This subset was suggested to be a counterpart of
mouse neutrophil precursors, but unfortunately the neutrophil
potential of this possible precursor was not evaluated.
Here, we decided to take advantage of mass cytometry and
viSNE (visualization of t-distributed stochastic neighbor embed-
ding) automated mapping to identify and study new NePs in
mouse and human BM.
RESULTS
Automated Single-Cell Analysis of Lin CD117+ Ly6A/E
Cells Identifies a Distinct NeP Population
We analyzed mouse BM using mass cytometry with the purpose
of identifying all NePs. We developed an antibody panel, shown
in Table S1, that measures 39 parameters simultaneously and
used it to perform CyTOF mass cytometry on healthy mouse
BM. We used viSNE automated analysis to study CD45+ BM
cells and found a portion of CD117(c-Kit)+ cells that had close
relation to Ly6G+ cells (Figure S1A). Interestingly, CD34+ GMP
clustered with different populations, including the Ly6G-
enriched population and the CD115-enriched population (Fig-
ure S1B). These results agree with the reported observation
that CD115+ MDP overlaps with CMP/GMP (Auffray et al.,
2009) and, more important, suggest that the GMP fraction has
NeP potential. We then focused exclusively on myeloid cells by
examining the Lin CD117+ Ly6A/E fraction of LK cells, which
contains all myeloid cell progenitors (Figure S1C). Using viSNE2330 Cell Reports 24, 2329–2341, August 28, 2018automated unbiased analysis, we found five distinct clusters of
cells in Lin CD117+ Ly6A/E cells, which we labeled as clusters
#A–#E in Figure 1A. Each of these clusters expresses distinctive
biomarkers that uniquely define specific myeloid cell types.
Siglec F (cluster #A) marks eosinophils, CD115 (cluster #B)
marks monocytes, Ly6G (cluster #C) marks neutrophils, FcεRIa
(cluster #D) marks mast cells and basophils, and CD16/32 and
CD34 (cluster #E) marks both CMP and GMP. The neutrophil-
specific antigen, Ly6G, is observed in a continuum from negative
to high expression in cluster #C, suggesting the presence of NeP
and precursors within this cluster (Kim et al., 2017; Satake et al.,
2012; Sturge et al., 2015; Yáñez et al., 2015).We confirmed these
results using conventional flow cytometry (Figures S2A and
S2B).
Because we were interested in identifying NePs, we focused
our efforts on further analysis of cluster #C, which showed a con-
tinuum of Ly6G expression. Using PhenoGraph, a second unbi-
ased clustering algorithm (Chen et al., 2016; Levine et al., 2015),
we found that cluster #C consists of two major populations that
display a continuum of Ly6G, Ly6C, and Ly6B expression (Fig-
ure 1B). These Ly6 proteins are highly expressed in mature neu-
trophils and their precursors (Kim et al., 2017; Lee et al., 2013).
We developed a conventional flow cytometry gating strategy,
shown in Figure 1C, to isolate with purity cluster #C cells
(Lin CD117+ Ly6A/E Siglec F FcεRIa CD16/32+ Ly6B+
CD162lo CD48lo Ly6Clo CD115) from BM. This cell population,
when backgated onto a viSNE map, fell exclusively into cluster
#C (Figure 1C).
ScRNA-Seq Analysis of Cluster #C Reveals Two Major
Subpopulations, #C1 and #C2
To closely investigate cluster #C, we sorted cluster #C cells for
scRNA-seq.We found two primary subpopulations within cluster
#C, #C1 and #C2 (Figure 2A), by scRNA-seq. Notably, #C1
shows low Ly6g expression at the mRNA level (Figure 2A), which
confirms our low Ly6G protein expression in this cluster found by
mass cytometry (Figure 1B).
Using these data, we were able to design a flow cytometry
panel (Figure 2B) that allowed us to isolate both #C1 and #C2
as well as other Lin CD117+ Ly6A/E cell fractions for further
detailed study. Cluster #C1 is Lin CD117+ Ly6A/E Siglec
F FcεRIa CD16/32+ Ly6B+ CD11a+ (LFA1a+) CD162lo CD48lo
Ly6Clo CD115 Ly6G, and cluster #C2 is LinCD117+ Ly6A/E
Siglec F FcεRIa CD16/32+ Ly6B+ CD11a+ (LFA1a+) Ly6G+.
On the basis of surface marker expression patterns, we predict
#C1 and #C2 as NeP candidates.
As identified in Figure 1A, cluster #E is enriched with CD16/
32CD34+ CMPs, and cluster #B is enrichedwith CD115+mono-
cyte progenitors. We performed bulk RNA-seq for transcriptome
analysis on #C1 and #C2 and analyzed #E and #B cells as control
groups. BM neutrophils (BM Neuts) containing immature and
mature neutrophils were also sorted from the same donors for
analysis. We found that #C1 expresses high levels of GMP
genes, including Egr1, Fosb, Jun, Gata2, and Gata1, as well as
genes that are shown to be critical for neutrophil development,
including Gfi1, Cebpa, Cebpe, Per3, and Ets1 (Avellino et al.,
2016; Buenrostro et al., 2018; Evrard et al., 2018; Horman
et al., 2009; Olsson et al., 2016; Radomska et al., 1998; Zhang
Figure 1. Automated Single-Cell Analysis of
Lin CD117+ Ly6A/E Cells in Bone Marrow
Identifies a Distinct Neutrophil Progenitor
Population
(A) ViSNE defines a largest cluster #C of the five
subsets in Lin CD117+ Ly6A/E cells from murine
BM using mass cytometry (CyTOF). BM cells iso-
lated from C57BL/6J donors were stained with the
antibody panel shown in Table S1. ViSNE maps of
Lin CD117+ Ly6A/E cells are shown as dot
overlays to display the five automated clusters
(#A–#E). Ly6G expression pattern is shown on
viSNE map of Lin CD117+ Ly6A/E cells as
spectrum colored dots. The expression patterns of
the indicated markers are shown as histogram
overlays of each cluster. Results are representative
of two independent experiments (n = 6 mice each).
(See CyTOF panel in Table S1, CyTOF gating
strategy in Figure S1, and flow cytometry gating
strategy in Figure S2.)
(B) PhenoGraph defines two subpopulations of
cluster #C using mass cytometry (CyTOF). Left:
two PhenoGraph meta-clusters present two
distinct populations (1, 2) in cluster #C. Right:
expression profile of Ly6G, Ly6C, and Ly6B for
randomly selected cells in each cluster is visual-
ized on the first component of a nonlinear dimen-
sionality reduction isomap (the regression black
line estimated using the generalized linear model is
added for each marker).
(C) FACS gating strategy for cluster #C using mass
cytometry (CyTOF). Manually gated cluster #C is
backgated to automated viSNE map for validation.
(See flow cytometry gating strategy in Figure S2C.)et al., 1997). Genes that are critical for monocyte development,
such as Irf8 (Olsson et al., 2016; Yáñez et al., 2015), on the other
hand, show low expression in #C1 and #C2. Interestingly, #C2
cells have lost expression of the GMP gene signature, while
the neutrophil gene signature increased in #C2 cells to levels
comparable with those of BM Neuts.
We next wanted to focus on the hierarchical structure of #C1
and #C2 within the neutrophil developmental lineage. Fre-
quencies of #C1 are lowest in BM, followed by #C2 (Figure S3A).
Comparison of #C1 and #C2 by flow cytometry showed a
gradient of Ly6G expression from negative in #C1 to intermedi-Cell Repate in #C2 to high in mature BM Neuts,
whereas CXCR2 is expressed only by
terminally differentiated BM Neuts (Fig-
ure S3A). Reconstruction in three dimen-
sions of the nuclear architecture of #C1
and #C2 cells suggests more stem cell-
like morphology than that of mature BM
Neuts and blood neutrophils (blood
Neuts) (Figure S3B). #C1 has more stem
cell-like nuclear morphology and higher
Ki67 expression and nuclear integration
(Figures 2C and S3C) than does #C2,
BM Neuts, and blood Neuts, suggesting
an early stage of development for #C1.These data suggest that #C1 lies earlier in the neutrophil devel-
opmental hierarchy and may partially overlap with GMP from
the classic myeloid progenitor paradigm. #C2, however, may
represent a transitional intermediate progenitor between #C1
and terminally differentiated neutrophils in mouse BM. Thus,
we then decided to focus on #C1 cells as the candidate for the
early-stage committed NeP.
The selective neutrophil potency of #C1 cells was first tested
by examining in vitro methylcellulose colony-forming unit for-
mation (Figure 2E). All donor cell fractions were sorted using
fluorescence-activated cell sorting (FACS) using the gatingorts 24, 2329–2341, August 28, 2018 2331
Figure 2. ScRNA-Seq Analysis of Cluster #C
Reveals Two Major Subpopulations, #C1
and #C2
(A) Single-cell RNA sequencing (scRNA-seq) un-
covers the heterogeneity of cluster #C. Twenty
thousand cluster #C cells were sorted from
healthy wild-type mouse BM for scRNA-seq
assay (three biological triplicates, two technical
replicates). FACS strategies for cluster #C are
shown in Figure 1C using mass cytometry and
Figure S2C using flow cytometry. Left: t-distrib-
uted stochastic neighbor embedding (t-SNE) two-
dimensional (2D) plots, obtained applying Seurat
scRNA-seq analysis R package for the scRNA-
seq data, showing two main clusters corre-
sponding to subsets of cluster #C (n = 16,268
cells; #C1, 2,149 cells [green]; #C2, 14,089 cells
[salmon]). Right: heatmap shows top 40 differen-
tially expressed genes in each cluster. Black box
highlights Ly6G expression. Log2 fold change of
each gene expression is relative to the entire
dataset.
(B) FACS gating strategy for clusters #A and #D,
#B, #C1, #C2, and #E using mass cytometry
(CyTOF). Manually gated clusters are backgated
to automated viSNE map for validation. (See flow
cytometry gating strategy in Figure S3D.)
(C) RNA-seq shows upregulation of important
neutrophil lineage-decision genes in #C1 and
#C2. Clusters #C1, #C2, and #E and BM Neuts
were sorted from healthy wild-type mice BM for
RNA-seq. FACS strategies for these cell types are
shown in Figure 2B using mass cytometry and
Figure S3D using flow cytometry. Heatmap
showing expression of important development
transcriptional factors for myeloid cell develop-
ment in sorted populations by RNA-seq. Black
box highlights expression of important neutrophil
lineage-decision genes (bold) in #C1 and #C2.
Cebpa (green) expression is higher in #C1
compared with #C2. Cebpe (orange) expression
is lower in #C1 compared with #C2. Z score
normalization from CPM (counts per million)
expression level (log2 scale) was quantified from
RNA-seq.
(D) Confocal microscopy detected Ki67 localiza-
tion within the nuclei in clusters #C1and #C2.
#C1, #C2, BM Neuts, and blood Neuts were
sorted and stained with antibodies to Ki67 (red),
and DNA was labeled with Hoechst (blue). FACS
strategies for these cell types are shown in Figure 2B using mass cytometry and Figure S3D using flow cytometry. IgG-stained cells served as a negative
control. Scale bar, 5 mm.
(E) Clusters #C1 and #C2 cells produce only neutrophils in vitro. Clusters #C1, #C2, #B (CD115+), #A, #D, and #E cells were sorted from wild-type mice
and diluted to single-cell suspensions. FACS strategies for these cell types are shown in Figure 2B using mass cytometry and Figure S3D using flow
cytometry. Single cells of each cluster were cultured in methylcellulose-based medium. Numbers of colonies generated from the indicated progenitors were
counted at day 10 of culture. Contingency plot shows mean value of six independent experiments (each contains three biological triplicates). (See also
Figure S3.)strategy described in Figure 2B. CD115+ CD117+ cells are
monocyte progenitors and are located within cluster #B, so
the CD115+ portion of cluster #B was sorted as monocyte pro-
genitors (Figure S4A). Clusters #A, #D, and #E were collected
together as a control group. As shown in Figure 2E, #C1 single
cells generate colony-forming unit-granulocyte (CFU-G)
in methylcellulose-based medium with 100% purity, but not2332 Cell Reports 24, 2329–2341, August 28, 2018colony-forming unit-macrophage (CFU-M) or colony-forming
unit-granulocyte, macrophage (CFU-GM). Similar results were
also observed with #C2. Cluster #B (CD115+) cells were able
to generate CFU-M only, as expected. The #A#D#E control
group generated all three types of colonies. These results sug-
gest that #C1 cells have restricted granulocyte potency in vitro
that lasts at least 10 days.
Figure 3. Clusters #C1 and #C2 Cells Are
Committed Hierarchical Unipotent Progeni-
tors for Neutrophil Production In Vivo
(A) Scheme showing the experimental procedure.
Clusters #C1 and #C2 were sorted from CD45.2
donors and adoptively transferred into irradiated
wild-type CD45.1 recipient mice. Clusters #B
(CD115+), #A, #D, and #E cells were sorted from
the same donors for this experiment and served as
controls. FACS strategies for these cell types are
shown in Figure 2B using mass cytometry and
Figure S3D using flow cytometry. Each recipient
group includes 25 mice. Each recipient received
50,000 donor cells. After the transfer, peripheral
blood was collected for flow cytometry of CD45.2+
cells from five recipients of each group at days (D)
5, 7, 12, 14, and 28. CD45.2+ cells were evaluated
for the donor cell-derived monocytes (CD115+),
neutrophils (Ly6G+), eosinophils (Siglec F+), and
basophils (FcεRIa+). N = 5 mice for each time point
in each group. (See FACS strategy in Figures S3D
and S4A.)
(B) Clusters #C1 and #C2 cells produce only neu-
trophils in vivo. Representative plots show the
appearance of neutrophils and monocytes in each
recipient group at the time points indicated. Re-
sults are representative of two independent ex-
periments. (See quantification in Figure S4.)
(C) Cluster #C1 produces #C2 cells in vivo. #C1
cells were sorted from CD45.2 donors and adop-
tively transferred into irradiated wild-type CD45.1
recipient mice. FACS strategies for #C1 cells are
shown in Figure 2B using mass cytometry and
Figure S3D using flow cytometry. After transfer,
BM was collected for flow cytometry of CD45.2+
cells from three recipients of each group at days
(D) 3, 5, 7, and 14. CD117+CD45.2+ cells were
evaluated for the donor #C1 homing to bone
marrow and differentiation into #C2 cells. Expres-
sion in recipients of #C1 and #C2 cells are
identified by the panel shown in Figures 2B and
S3D and overlaid for display. #C2 differentiation
into #C2 cells are shown as the ratio of #C2 to #C1
(R#C2/#C1). (See also Figure S4.)Cluster #C1 Is the Early-Stage Committed Unipotent
NeP In Vivo
We next analyzed the function of #C1 in generating neutrophils
in vivo using adoptive transfer approaches. The experimental
scheme is shown in Figure 3A. The cell populations described
in Figure 2E were FACS-sorted from the same donor mice.
Each of the four cell groups was adoptively transferred into a
group of sub-lethally irradiated CD45.1 recipient mice. Blood
from each group was examined at days 5, 7, 12, 14, and 28
by flow cytometry for appearance of donor-derived progeny.
The flow cytometry gating for all donor cell progeny is shown
in representative plots of the #A#D#E recipient group in Fig-
ure 3A (right). Donor cells (CD45.2+) appeared in blood as earlyCell Repas day 5 and peaked at day 14 (Fig-
ure 3A, right, and Figure S4B, left). Donor
cells were analyzed for expression of key
markers for myeloid progenies: mono-cytes (Mo, CD115+), neutrophils (Ne, Ly6G+), eosinophils (Eo,
Siglec F+), or basophils (Ba, FcεRIa+).
Donor-derived neutrophils appeared in recipient blood at
day 5 and day 7 post-adoptive transfer in the groups reconsti-
tuted with #C1 (green) and #C2 (orange), suggesting neutro-
phil potency in both populations and slower kinetics of the
#C1 cells in producing neutrophils (Figure 3B). NePs from
these progenitors constitute nearly 100% of CD45.2+ donor
cell-derived leukocytes in the #C1 recipients (Figure S4B,
middle). In the control groups, #B (CD115+) produced only
monocytes and did not produce neutrophils, and #A#D#E
produced both neutrophils and monocytes (Figures 3B and
S4B, red and black). These results illustrate the restrictedorts 24, 2329–2341, August 28, 2018 2333
Figure 4. Cluster #C1NeP and #C2Cells Are
Increased in BM with Tumor and Promote
Tumor Growth In Vivo
(A) Cluster #C1 NeP and #C2 cells are increased in
BMof tumor-bearingmice. Five hundred thousand
B16F10 melanoma cells were s.c. injected into the
rear flank of wild-type recipient mice for primary
tumor growth. The frequencies of clusters #E, #B
(CD115+), #C1, and #C2were detected in BM from
tumor-bearing mice at 14 days post-injection
(open bars) or their healthy counterparts (solid
bars). N = 15. Error bars indicate mean (SD). (See
also Figure S5.)
(B) Left: scheme showing the experiment pro-
cedure. Clusters #E, #B (CD115+), #C1, and #C2
were sorted from the same CD45.2 wild-type do-
nors and were adoptively transferred into sub-
lethally irradiated congenic CD45.1 recipients.
FACS strategies for these cell types are shown in
Figure 2B using mass cytometry and Figure S3D
using flow cytometry. Each recipient received
53 104 donor cells. The next day, 33 105 B16F10
melanoma cancer cells were s.c. injected into
each recipient mouse. Right: the tumor volume in
each recipient was measured at 12 and 22 days
post-injection. Results are representative of two
independent experiments. N = 5 mice in each
group. Error bars indicate mean (SD).
(C)Clusters #C1and#C2cells infiltrate to tumor and
generate PD-L1-positive progenies. At day 22 (D22)
after the adoptive transfer, the tumors were har-
vested from recipients. Live singlet cells in tumor
wereevaluatedusingflowcytometry.CD45+donor-
derived cells were analyzed for PD-L1 expression.
#C1, #C2, and donor-derived neutrophils were
identified with the panel from Figures 2B and S3D
and overlaid for display. (See also Figure S5.)unipotency of #C1 and #C2 progenitors to generate solely
neutrophils.
Neutrophil production peaks at day 14 in #C2 recipients, but at
day 28, neutrophils vanished from the #C2 recipients, suggesting
limited developmental potency of #C2 (Figure S4B, right). How-
ever, in #C1 recipients, neutrophil production continued to day
28, our latest time point, indicating that the #C1 progenitors
have longer termpotency. This long-term potency of #C1 is com-
parable with the #A#D#E fractions of LinCD117+ Ly6A/E cells,
which contains CMP. To further determine that #C1 cells give
rise to #C2 cells, we FACS-sorted only the #C1 cells (using the
gating strategy shown in Figure 2B) from CD45.2 BM and adop-
tively transferred these CD45.2+ #C1 cells into CD45.1 recipi-
ents. We tracked the fate of the CD45.2+ #C1 donor cells by
examine the recipients’ peripheral and BM for the production
of #C2 after the adoptive transfer. As shown in Figures 3C and
S4C (top), #C1 cells infiltrated into spleen quickly by day 3 and
appeared in BM 5 days after adoptive transfer. Importantly, a
portion of the CD45+ #C1 donor cells started to generate #C2
very quickly after adoptive transfer, while some #C1 cells seeded
in the BM (Figures S4C and 3C, bottom), again confirming that
#C1 is the early-stage committed NeP.
Thus, by using high-dimensional mass cytometry and scRNA-
seq approaches, as well as adoptive transfers in vivo, we have2334 Cell Reports 24, 2329–2341, August 28, 2018discovered an early-stage committed unipotent NeP (#C1,
termed NeP) in mouse BM. This progenitor can be identified as
Lin CD117+ Ly6A/E Siglec F FcεRIa CD16/32+ Ly6B+
CD11a+ CD162lo CD48lo Ly6Clo CD115 Ly6G.
Cluster #C1 Cells Are Increased in BM and in Periphery
with Tumor and Promote Tumor Growth In Vivo
Granulopoiesis is associated with cancer, with neutrophils hav-
ing both pro-tumoral and anti-tumoral roles (Casbon et al.,
2015; Hagerling and Werb, 2016; Sagiv et al., 2015). We
wondered what role #C1 NeP would have in tumorigenesis
in vivo. We first asked whether #C1 or #C2 cells were increased
in BM in a melanoma mouse model. We injected B16F10 tumor
cells subcutaneously (s.c.) into the rear flank of wild-type C57BL/
6J mice (tumor). Age- and gender-matched wild-type mice
received D-PBS to serve as healthy controls (healthy). At
14 days post-injection, we found a significant expansion of
#C1 NeP and #C2 cells and a slight increase of #B (CD115+),
but not #E (CMP) cells, in the BM of tumor-bearing mice (Fig-
ure 4A), indicating that in the setting of cancer, myelopoiesis is
strongly geared toward the neutrophil lineage. Interestingly, we
detected minimal numbers of cluster #C cells (less than 0.02%
of all CD45+ cells in the periphery) of healthy mice, whereas
#C cells are increased 10-fold in periphery of tumor-bearing
mice (Figure S5A), suggesting that there is increased production
and egress of these NePs from BM to periphery in response to
the tumor microenvironment. To test whether NeP can directly
contribute to tumor growth, #C1 NeP cells, #C2 cells, #B
(CD115+) cells, and #E cells were sorted from CD45.2 wild-type
donor mice and adoptively transferred into irradiated CD45.1
recipient healthymice. At day 1 after donor cell transfer, recipient
mice were injected s.c. with B16F10 tumor cells into the rear
flank. Tumor size wasmeasured at days 12 and 22 after injection
(Figure 4B, left). As shown in Figure 4B (right), mice receiving #C1
cells or #C2 cells showed increased tumor growth compared to
#B (CD115+) cells or #E cells (CMP) at both time points. #C1
NeP promoted more potent tumor growth at the later time point
compared with #C2 cells. At day 22 after tumor injection, tumors
were harvested for detection of donor-derived cells. More #C1
NeP-derived cells infiltrated the tumor than did #C2 cells, and
more than 30% of these #C1 NeP-derived cells expressed PD-
L1, an inhibitory costimulatory molecule that contributes to im-
mune suppression (Figure 4C). Further analysis revealed that
tumor-infiltrated #C1 cells were able to maintain their stem cell
phenotype as well as produce PD-L1+ #C2 and CD117Ly6G+
neutrophils. #C2 cells were also able to promote tumor growth
via the same mechanism but to a lesser degree, whereas other
cell types did not infiltrate the tumor (#B) and showed minimal
PD-L1 expression (#E) (Figure S5B). Thus, #C1 NeP progenitors
respond to melanoma tumor cues and have tumor-promoting
functions by producing immune-suppressive progenies.
Discovery of a Heterogeneous CD66b+CD117+ CD38+
CD34+/ Progenitor-like Cell Fraction in Human BM
On the basis of our cancer findings inmice showing the relevance
of NePs to tumor growth, we next decided to look for NePs in
human BM. Human CMP and GMP express CD34, CD38, and
CD117 and mirror the murine CMP/GMP paradigm in myeloid
cell production (Doulatov et al., 2010; Edvardsson et al., 2006;
Manz et al., 2002). CD66b is an important marker for neutrophil
identification. However, it is often excluded from flow cytometry
panels geared toward discovery of hematopoietic progenitors.
We decided to retain this marker in our search for the early
NeP in human BM. We developed a flow cytometry panel to
investigate the neutrophil lineage by focusing on CD45+ cells
that excluded other hematopoietic stem/progenitor cells
(HSPCs), including hematopoietic stem cells (HSC), multipotent
progenitors (MPPs), CLP, multilymphoid progenitor (MLP),
lymphoid-primed MPPs (LMPP), MEP, eosinophil progenitor
(EoP), CMP, GMP, cMoP, andMDP and other terminally differen-
tiated leukocytes (Doulatov et al., 2012; Edvardsson et al., 2006;
Hoebeke et al., 2007; Kawamura et al., 2017; Kohn et al., 2012;
Lee et al., 2015; Manz et al., 2002; Mori et al., 2009; Notta
et al., 2016; Weiskopf et al., 2016). In this panel, all gates were
strictly controlled with both single-color and fluorescence minus
one (FMO) controls (Figure S6A). Indeed, we discovered that
human BM contains a CD66b+ population that expresses
CD117 (Figure 5A), suggesting the presence of CD66b+ stem
cell progenitors within human BM (termed here as hNeP). This
CD66b+CD117+ population expresses high levels of CD38+ (Fig-
ure S6B), an important stem cell marker that is exclusively ex-
pressed by CMP/GMP (Doulatov et al., 2010, 2012; Kohn et al.,2012; Manz et al., 2002), suggesting that this population is
committed to the myeloid lineage for development. ScRNA-seq
analysis of this CD66b+CD117+ human NeP population revealed
twomajor subsets that showed either positive (subset A) or nega-
tive (subset B) expression of CD34 (Figure 5B). Interestingly,
lower CD34 gene expression in subset B is associated with
increased expression of neutrophil-specific genes such as
ELANE and LYZ (Figure 5B). We then confirmed the CD34+ and
CD34 subsets suggested by scRNA-seq by flow cytometry
(Figure 6C). Both subsets appeared positive for Ki67 localization
in the nuclei, suggesting active proliferation, with a slightly higher
(about 1.3-fold) Ki67 mean fluorescence intensity value in CD34+
hNeP compared with CD34 hNeP (Figure 5D).
Both hNeP Subsets Produce Only Neutrophils in NSG-
SGM3 Mice
We then examined the neutrophil potency of both CD34+ and
CD34 hNeP subsets in vivo by performing adoptive transfers
of each subset into NSG-SGM3 (NSG-M3) mice. The triple trans-
genic NSG-M3 mice are immunodeficient NOD scid gamma
(NSG) mice that express the human cytokines interleukin-3
(IL-3), granulocyte/macrophage-stimulating factor (GM-CSF),
and SCF, also known as KITLG. This mousemodel supports sta-
ble engraftment of the human hematopoietic system, including
the myeloid lineage (Billerbeck et al., 2011; Coughlan et al.,
2016). The two subsets were isolated from fresh human BM by
FACS using the sorting panel in Figure 5 and transferred into
two groups of recipient NSG-M3 mice. Peripheral blood of
each NSG-M3 recipient mouse was collected on days 5, 7, 14,
and 28 for flow cytometry analysis (Figure 6A). To analyze the
progeny produced, we used a control group of NSG-M3 recip-
ient mice that received all CD34+ HSPCs (which contain progen-
itors for all leukocyte cell types). The blood of this control group
was analyzed for monocyte (Mo), neutrophils (Ne), eosinophils
(Eo), and lymphocytes (Ly), including T cells, B cells, and natural
killer (NK) cells using the flow cytometry panel shown in Figure
S6C. This flow cytometry panel is then used for the analysis of
hNeP recipient blood. After adoptive transfer, CD66b+ cells
were detected in both CD34+ hNeP and CD34 hNeP recipients,
but no other cell types were expressed (Figure 6B), illustrating
that both hNeP subsets are unipotent progenitors that produce
only neutrophils. Repopulation of the neutrophil pool by either
hNeP progenitor subset occurred quickly after the adoptive
transfer (day 5) and lasted to day 28 (Figure 6B), indicating rela-
tively long-term neutrophil unipotency of both progenitor sub-
sets. These data demonstrate that the CD66b+ CD117+ CD38+
CD34+/ fraction in human BM cells contains the unipotent
human NeP (hNeP) that occupies about 1%–3% of CD45+ cells
in human BM under homeostatic conditions.
hNeP Increase in Melanoma Patient Blood and Promote
Early Osteosarcoma Tumor Growth in Humanized NSG-
M3 Mice
We of course wanted to see if hNeP played a role in
tumorigenesis. First, we analyzed blood from human subjects
withmelanoma for the presence of hNeP (Table S2). Flow cytom-
etry analysis of blood from melanoma versus healthy patients
blood using the panel in Figure 5 revealed the presence ofCell Reports 24, 2329–2341, August 28, 2018 2335
Figure 5. Human BM Contains a CD66b+
CD117+ hNeP Fraction that Contains CD34+
and CD34 Subsets
(A) Flow cytometry analysis of healthy human BM
uncovers a heterogeneous LinCD66b+CD117+
hNeP fraction. Dump antibody cocktail contains
antibodies against markers that are expressed by
HSC (CD90 [Thy1]), lymphocytes and their pro-
genitors (CD3, CD19, CD56, CD161, CD7, and
CD127 [IL-7Ra]), erythrocytes and their pro-
genitors (CD41 and CD235a [glycophorin A]),
eosinophils/basophils and their progenitors
(Siglec 8, FcεRIa, and CD125 [IL-5Ra]), CMP/GMP
and monocyte progenitors (CD123 [IL-3Ra]), DCs,
and macrophages (CD11c and CD169). (See also
Figure S6.)
(B) ScRNA-seq analysis of LinCD66b+CD117+
hNeP cells reveals two major subpopulations,
subset A and subset B. Twenty thousand hNeP
cells were FACS-sorted from healthy human BM
for scRNA-seq. Heatmap shows top 40 differen-
tially expressed genes in each cluster. Log2 fold
change of each gene expression is relative to the
entire dataset. Two biological triplicates, two
technical replicates.
(C) LinCD66b+CD117+ hNeP were divided into
CD34+ subset and CD34 subset by flow cy-
tometry. (D) Confocal microscopy was used to
detect Ki67 localization (red) within the nuclei (blue)
in CD34+ subset and CD34 subset using anti-
bodies to Ki67 and Hoechst. IgG-stained cells
served as negative control. Scale bar, 5 mm.CD66b+CD117+ cells (about 1% of circulating CD45+ cells) in the
blood of healthy donors (Figure 7A). The frequency of these
hNeP was significantly elevated in the blood of melanoma pa-
tients, with frequencies of about 3%–9% of circulating CD45+
cells (Figure 7A). We did not observe direct correlations between
the hNeP frequencies and gender or age despite the small pool
of donors (data not shown). Importantly, CD34+ hNeP were
barely detected in healthy donor blood but were elevated in
the blood of melanoma patients (Figure 7A). This increase of
hNeP cells in human melanoma patient blood is consistent
with what we have observed for mouse NeP in our mouse mela-
noma model (Figure S5A), suggesting that the hNeP could serve
as a biomarker candidate for early cancer detection.
Then we examined the role of hNeP in regulating multiple solid
tumor types growth to see if the tumor-promoting role of NePs
was relevant in more than one tumor type using NSG-M3 mice.
A high neutrophil-to-lymphocyte ratio is an indicator of worse
prognosis in sarcomas (Anderson, 2017). Here we used osteo-
sarcoma as model of solid tumor. Shown in Figure 7B (left),
both CD34+ hNeP and CD34 hNeP were isolated from human
BM and adoptively transferred into NSG-M3 recipient mice.
Two different control groups were used in this experiment: one
control group received only PBS for adoptive transfer, and the
other group received human cMoP as a source of human
monocyte progenitors. Human cMoP were sorted from the
same human BM donor using the panel described previously2336 Cell Reports 24, 2329–2341, August 28, 2018(Kawamura et al., 2017). One day after adoptive transfer of pro-
genitors, 1 3 106 human osteosarcoma cells were injected s.c.
into the rear flank of mice in all four recipient groups. The tumor
size wasmeasured 10 days after injection. As shown in Figure 7B
(right), mice receiving either CD34+ hNeP or CD34 hNeP cells
showed an increase in tumor growth compared with recipient
mice receiving cMoP or PBS as a control. These data
are concomitant with the mouse data shown in Figure 4B, sug-
gesting that hNeP, the counterpart of mouse NeP, also are
pro-tumoral and mediate solid tumor growth.
Finally, as we observed increased tumor size with hNeP adop-
tive transfer, we askedwhether hNeP promoted tumor growth by
blunting T cell activation. CD34+ hNeP, CD34 hNeP, or mature
neutrophils were FACS-sorted from fresh human BM and co-
cultured with purified CD3+ T cells isolated from other donor’s
blood in the presence of anti-CD3. At 24 hr after co-culture,
mature neutrophils efficiently induced CD3+ T cell activation as
measured by CD69+ expression (Figure 7C). CD3+ T cells
co-cultured with CD34+ hNeP expressed very low levels of
CD69 compared with the mature neutrophil co-culture group,
suggesting significant induction of suppression in this group.
CD34 hNeP inhibited T cell activation to a lesser extent
compared with CD34+ hNeP (Figure 7C). These data suggest
that compared with mature neutrophils, hNeP are possibly
immunosuppressive and promote tumorigenesis by attenuating
tumor-destructive, pro-inflammatory T cell activation.
Figure 6. hNeP Produce Only Neutrophils in
NSG-SGM3 Mice In Vivo
(A) Scheme showing the experimental procedure.
CD34+ hNeP and CD34 hNeP subsets identified
in Figure 5C were sorted from healthy human BM
and adoptively transferred into NSG-M3 recipient
mice. Each recipient mouse received 25,000 donor
human hNeP progenitor cells. After the transfer,
peripheral blood was collected from each recipient
via saphenous vein for flow cytometry on days (D)
5, 7, 14, and 28.
(B) Representative plots show the appearance of
monocytes (CD86+ CD66b), neutrophils (CD86
Siglec 8 CD66b+), eosinophils (Siglec 8+), and
lymphocytes (hLy+) in each recipient group at the
time points indicated. hLy antibody cocktail con-
tains CD3, CD19, and CD56. N = 10 mice for each
group. (See flow cytometry gating strategy in Fig-
ure S6C.)DISCUSSION
In this paper, we report the discovery of a very early stage
committed unipotent NeP that is present in mouse and human
BM. We found that both the mouse and human NeP promoted
primary tumor growth in vivo in established cancer models.
Furthermore, we identified the presence of the human NeP
(hNeP) in the blood of patients with recently diagnosed
melanoma, suggesting that this hNeP is released from the BM
in patients with cancer and can be readily identified in human
blood.
Importantly, we found a tumor-promoting role for this early-
stage NeP in both mice and humans. In tumor-bearing mice,
frequencies of this NeP are increased in BM, suggesting aberrant
myelopoiesis in response to tumor growth (Figure 4A). These re-
sults are consistent with previous studies that suggest that the
tumor reprograms GMP to cause increased production of
tumor-associated neutrophils (Casbon et al., 2015). Interest-
ingly, we found that tumor-induced myelopoiesis is specific
for NeP in mouse BM (Figure 4A). Furthermore, when adoptively
transferred into recipient mice, the NeP significantly promoted
melanoma tumor growth compared with other myeloid progeni-
tors and was also found in the periphery as well as in the tumor,
suggesting egress from the BM and infiltration to the tumor.
Some of the #C1 and #C2 cells remain undifferentiated
once they infiltrate into tumor and meanwhile start to express
PD-L1 (Figures S5 and 4C). We also detected similar tumor-Cell Reppromoting effects of hNeP in human
tumorigenesis using an NSG-humanized
mouse model. After adoptive transfer,
hNeP significantly promoted osteosar-
coma tumor growth in NSG mice
compared with other myeloid progenitors
(Figure 7B). Importantly, we observed a
3- to 9-fold increase of hNeP in the blood
of patients diagnosed with melanoma.
This result is consistent with our observa-
tion of increased NeP in mouse peripheryin response to tumor growth (Figure S5) and suggests that this
hNeP could be used in some manner as a biomarker for early
cancer detection.
The earliest committed NeP has remained elusive for de-
cades. Most studies have focused on murine hematopoiesis.
In this regard, the classic model of hematopoiesis shows
that LSK+ (LinCD117+Ly6A/E+CD127) HSPCs give rise to
CLP (LinCD117loLy6A/E+CD127+) for lymphopoiesis and to
the LinCD117+Ly6A/ECD127 HSPCs for myelopoiesis
(Weissman et al., 2001). A higher level of heterogeneity exists
within the linCD117+Ly6A/ECD127 population, and the
committed long-term monocyte progenitor partially overlaps
with this HSPC fraction (Auffray et al., 2009; Olsson et al.,
2016; Paul et al., 2015; Pronk et al., 2007). Indeed, further ex-
amination of the LinCD117+Ly6A/E HSPC fraction by mass
cytometry showed five possibly committed myeloid progeni-
tors (Figure 1A). Cluster #C in Figure 1A showed low to mod-
erate expression of Ly6G, suggesting a neutrophil lineage
potential for cells found within this cluster. This cluster was
not identified in earlier hematopoiesis studies, as the neutro-
phil marker Ly6G was routinely excluded from flow cytometry
panels at that time. ScRNA-seq analysis of this Ly6G-contain-
ing cluster #C further revealed two populations: an early-stage
progenitor (#C1) with stem cell morphology and little Ly6G
expression and a late-stage precursor (#C2) that expressed
low levels of Ly6G with morphological features similar to tran-
sient neutrophil precursors (Figures 2D and S3B) (Evrard et al.,orts 24, 2329–2341, August 28, 2018 2337
Figure 7. hNeP Is Increased in Melanoma
Patient Blood and Promotes Early Osteosar-
coma Tumor Growth in NSG-M3 Mice
(A) hNeP is increased in melanoma patient blood.
hNeP frequency was detected by flow cytometry in
peripheral blood collected from healthy donors
(n = 5) and melanoma patients (n = 5). Error bars
indicate mean ± SEM. (See donor information in
Table S2.)
(B) Left: scheme showing the experiment pro-
cedure. CD34+ hNeP subset, CD34 hNeP subset,
and human cMoP were FACS-sorted from healthy
human BM. The three populations were adoptively
transferred into NSG-M3 recipient mice. Each
recipient mouse received 25,000 donor human
progenitor cells. Blank control group received only
PBS for adoptive transfer. The next day, 1 3 106
143B human osteosarcoma cells were s.c. in-
jected into each recipient mouse. Right: the tumor
volume in each recipient was measured at 10 days
post-injection. N = 5 mice in each group. Error
bars indicate mean ± SEM.
(C) CD34+ hNeP cells blunt T cell activation. FACS
strategies for CD34+ hNeP and CD34 hNeP are
shown in Figures 5A and 5C using flow cytometry;
FACS strategies for mature neutrophils is shown in
Figure S7D using flow cytometry. Histogram
overlay of CD69 for CD3+ T cells cultured with
CD34+ hNeP, CD34 hNeP, and mature neutro-
phils, in the presence of anti-CD3 for 24 hr. CD3+
T cells alone cultured without anti-CD3 served as
the negative control group, and CD3+ T cells alone
cultured with anti-CD3, CD28 served as the posi-
tive control group for T cell activation.2018; Satake et al., 2012; Sturge et al., 2015; Yáñez et al.,
2015). Recently, a late-stage neutrophil precursor was
identified in BM of mice (Kim et al., 2017). We located this
population (termed by us as K.NeuP) on a viSNE map of
LinCD117+Ly6A/E HSPCs (Figure S7A). Surprisingly, we
found that this K.NeuP population was highly heterogeneous
and contained other myeloid progenitors. From our mass
cytometry data, we were able to generate a stringent flow cy-
tometry gating strategy (Figure S7A) that allowed us to
completely purify, with no contamination from other myeloid
lineages, both #C1 (NeP) and #C2 cells (late-stage precursors)
(Figure S7B) in order to demonstrate their neutrophil unipo-
tency. We also located the recently reported mouse neutrophil
precursor (termed by us as Ng.preNeu) (Evrard et al., 2018)
and aligned it with #C1 (NeP) and #C2 in the neutrophil devel-
opmental branch. ViSNE analysis suggested the mouse
Ng.preNeu shares phenotype that shares approximately 22%
similarity to #C1 NeP and is mostly similar to #C2 (Figure S7C).
The signature nuclear shape of the murine Ng.preNeu also2338 Cell Reports 24, 2329–2341, August 28, 2018closely resembles that of #C2 (Evrard
et al., 2018). In addition, we compared
the human Ng.preNeu (Evrard et al.,
2018) with the hNeP that we have
identified. The human Ng.preNeu does
not express CD117 and CD34 andtherefore does not overlap with the hNeP we identified (Fig-
ure S7D). Likely, the human Ng.preNeu represents a transient
precursor between hNeP and terminally differentiated neutro-
phils. This hypothesis is supported by our analysis shown
in Figure S7E that hNeP represents the lowest frequency
(1%–3%) of human BM CD45+ cells followed by Ng.preNeu
(4%–10%), immature neutrophils 20%–40%, and mature neu-
trophils 30%–40%.
The lifespan of human neutrophils is better studied than is
neutrophil heterogeneity. It is commonly recognized that the life-
span of neutrophils that are isolated by gradient separation
varies from hours to days (Bekkering, 2013; Pillay et al., 2010).
One possible hint we can take from this notion is that gradient
isolation may yield a heterogeneous neutrophil population
that contains neutrophil subsets and/or immature and mature
neutrophils that are at different differentiation stages. Indeed,
neutrophil heterogeneity has been suggested in both humans
and mice (Beyrau et al., 2012; Silvestre-Roig et al., 2016).
A few biological markers, such as CD49 or TCRa, b variants,
were suggested to identify certain neutrophil subsets in addition
to neutrophil markers Ly6G (mouse) and CD66b (human)
(Silvestre-Roig et al., 2016). However, neutrophil heterogeneity
is still not well defined. In this study, we focused on the unipo-
tency and the functions of NePs rather than the heterogeneity
of the produced neutrophil progeny. Although we know that
the identified NePs give rise to solely neutrophils, we have not
yet studied whether these progenitors give rise to specific sub-
sets of neutrophils, particularly in the setting of cancer. Hints
from our data suggest that these hNePNePsmay promote tumor
growth by suppressing T cell activation. Future studies will
further examine the mechanisms by which these hNeP subsets
influence T cell responses within the tumor microenvironment.
We also do not exclude the possibility that the NeP itself, once
egressed from the BM and present in the periphery, could
directly participate in the tumor-promoting effects we observed
(Figures 4 and 7).
In sum, using mass cytometry, we have identified an early-
stage committed unipotent NeP that is present in both mouse
and human BM. This discovery may drive new therapeutic
and pharmaceutical targets for neutrophil-related diseases
or treatment outcomes that are associated with chronic inflam-
mation. For example, neutropenia leads to high susceptibility to
infections and is often associated as a by-product of cancer
treatments (Lyman et al., 2014). Targeting hNeP could rescue
patients from undesirable neutropenia. In addition, our obser-
vation of increased hNeP in blood of melanoma patients could
assist in early detection for cancer diagnosis as a biomarker. As
this hNeP also displays tumor-promoting effects, we suggest
the possibility that this hNeP itself could be an immune-
oncology target, which opens a new field of therapeutic
discovery.STAR+METHODS
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scRNA-seq data This paper GEO: GSE117131
RNA-seq data This paper GEO: GSE117129
Experimental Models: Cell Lines
B16-F10 mouse Melanoma cell line ATCC Cat# CRL-6475
143B human Osteosarcoma cell line ATCC Cat# CRL-8303
Experimental Models: Organisms/Strains
Mouse: C57BL/6J The Jackson Laboratory Stock No: 000664
Mouse: B6.SJL-Ptprca Pepcb/BoyJ The Jackson Laboratory Stock No: 002014
Mouse: NOD.Cg-Prkdcscid Il2rgtm1WjlTg(CMV-
IL3,CSF2,KITLG)1Eav/MloySzJ
The Jackson Laboratory Stock No: 013062
Software and Algorithms









PhenoGraph Levine et al., 2015 https://doi.org/10.1016/j.cell.2015.05.047
Cytofkit v1.r.0 Chen et al., 2016 https://bioconductor.org/packages/
release/bioc/html/cytofkit.html
FlowJo (version 10.1r5) TreeStar http://flowjo.com/
Seurat (version 1.4) Rizzo, 2016; Satija
et al., 2015
https://satijalab.org/seurat/
FeatureCount R package v1.22.2 Liao et al., 2013 https://rdrr.io/bioc/Rsubread/man/
featureCounts.html
RSubread R package v1.30.5 Liao et al., 2013 http://bioconductor.org/packages/
release/bioc/html/Rsubread.html
edgeR v3.22.3 Robinson et al., 2010 https://bioconductor.org/packages/
release/bioc/html/edgeR.html
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
ZEN ZEISS https://www.zeiss.com/microscopy/int/
products/microscope-software/zen.html
HyVolution 2 Leica https://www.leica-microsystems.com/
products/confocal-microscopes/
details/product/hyvolution-2/downloads/
Image-Pro Premier Media Cybernetics http://www.mediacy.com/imagepro




GraphPad Prism 7 GraphPad Software http://www.graphpad.comCONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents may be directed to and will be fulfilled by lead contact Catherine C. Hedrick (hedrick@
lji.org).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
C57BL/6J, B6 CD45.1 congenic mice, and NSG-SGM3 mice were purchased from The Jackson Laboratory. Mice were fed a stan-
dard rodent chow diet and were housed in microisolator cages in a pathogen-free facility. Mice were euthanized by CO2 inhalation
followed by cervical dislocation. All experiments followed approved guidelines of the La Jolla Institute for Allergy and Immunology
Animal Care and Use Committee, and approval for use of rodents was obtained from the La Jolla Institute for Allergy and Immunology
according to criteria outlined in the Guide for the Care and Use of Laboratory Animals from the National Institutes of Health. Animals
were randomly assigned to groups from available mice bred in our facility or ordered from distributor. Experiments in this study used
male animals 6-10 weeks of age in good health. If animals were observed with non-experiment related health conditions (i.e., maloc-
clusion, injuries from fighting, etc.), animals were removed from study groups. For tumor studies, B16F10 melanoma cells and 143B
human osteosarcoma cells were obtained from ATCC. Cell lines were tested for being pathogen free. Cell lines were maintained
in DMEM medium containing 10% heat-inactivated FBS, 2 mmol/L l-glutamine, 1 mmol/L sodium pyruvate, 50 U/mL penicillin,
50 mg/mL streptomycin. For tumor injection, the hair around the tumor injection area of the 6-10 week old mice or adoptive transfer
recipients was removed before injection. For Figure 4A and S5A, 5 3 105 B16F10 cells were washed and resuspended in 100 ul
D-PBS and then SubQ injected into the rear flank of the mouse, and the tumor-bearing mice were euthanized by CO2 inhalation fol-
lowed by cervical dislocation at Day 14 post-tumor injection. For Figure 4B and S5B, 33 105 B16F10 cells were washed and resus-
pended in 100 ul DPBS and then SubQ injected into the rear flank of the mouse, and the tumor size were measured with a digital
caliper at Day 12 and Day 22 post-tumor injection. For Figures 7B and 1 3 106 143B human osteosarcoma cells were washed
and resuspended in 100 ul DPBS and then SubQ injected into the rear flank of the mouse, and the tumor size were measured
with a digital caliper at Day 10 post-tumor injection. Tumor volume was calculated using the formula V (volume) = D 3 d2/2 (D is
the largest measured tumor diameter and d is the smallestmeasured tumor diameter). Laboratory personnel were blinded to the iden-
tities of experimental groups during sample collection and analysis.
Human BM cells
Fresh BM samples of anonymous healthy adult donors were obtained from AllCells, Inc. (Alameda, CA). The cells were stained for
either flow cytometry or FACS-sorting following protocols described in the Flow Cytometry and Cell Sorting section.
Melanoma Patient Blood Collection
Blood from melanoma patients (no previous radiation, no prior chemo treatment) was collected in EDTA-tubes by the Biospecimen
Repository Core Facility (BRCF) at University of Kansas Cancer Center and delivered via overnight shipping. In the meantime, blood
from healthy donors were collected in EDTA-tubes in La Jolla Institute for Allergy and Immunology and stored and treated similarly as
control groups for the study. All blood samples were processed at the same time and cells were stained for flow cytometry followed
by the protocol described in the Flow Cytometry and Cell Sorting section.
Human Peripheral Blood Collection
EDTA-coated blood from healthy volunteers was obtained after written informed consent under the guidelines of the Institutional Re-
viewBoard of the La Jolla Institute for Allergy and Immunology and in accordancewith USDepartment of Health andHuman Servicese5 Cell Reports 24, 2329–2341.e1–e8, August 28, 2018
Policy for protection of Human Research Subjects (VD-057-0217). Cells were stained for flow cytometry followed by the protocol
described in the Flow Cytometry and Cell Sorting section.
METHOD DETAILS
Cell suspension for mass cytometry and flow cytometry
BM cells were harvested from femurs, and tibias of 6-10 week old mice. Bones were centrifuged for the collection of marrow. For the
adoptive transfer experiments, donor BM cells were collected and stained under sterile conditions. Peripheral blood was obtained by
cardiac puncture with an EDTA-coated syringe. For Figure 6B and S6B, a drop of blood was obtained from the saphenous vein of the
adoptive transferred NSG-SGM3 mice recipients. All samples (both mouse and human) were collected in ice cold D-PBS (GIBCO)
with 2 mM EDTA to prevent cation-dependent cell-cell adhesion. Prior to staining cells, cells were subject to a red blood cell lysis
(RBC lysis buffer, eBiosciences) at room temperature (5min x 1 for BMcells, 10min x 2 for blood cells). Cells werewashed and filtered
through a 70 mm strainer. Cell suspensions were prepared by sieving and gentle pipetting to reach final concentration of 33 106 cells
per 100 ul buffer.
Mass Cytometry Antibodies
Metal-conjugated antibodies were purchased directly from Fluidigm for available targets. For all other targets, purified antibodies
were purchased from the companies listed in Table S1. Antibody conjugations were prepared using the Maxpar Antibody Labeling
Kit according to the recommended protocol provided by Fluidigm. Maxpar-conjugated antibodies were stored in PBS-based anti-
body stabilization solution (Candor Biosciences) supplemented with 0.05% NaN3 at 4C. All antibodies were titrated before use.
Mass Cytometry (CyTOF)
For viability staining, cells were washed in PBS and stained with Cisplatin (Fluidigm) to a final concentration of 5 mM. Prior to surface
staining, anti-CD16/32 (151Eu) antibody was added to cell suspension in ice-cold staining buffer (PBS + 2mM EDTA + 0.1% BSA +
0.05%NaN3) to stain and block the Fc receptors for 15 min. The surface antibody cocktail listed in Table S1 was then added into the
cell suspension for 1h. The cells were then washed and fixed with 2% paraformaldehyde overnight at 4C. After fixation, cells were
washed in staining buffer and permeabilized using Foxp3/Transcription Factor Staining Buffer (eBioscience) for intracellular staining
according to the manufacturer’s protocol. Following permeabilization, cells were washed twice with 1 mL 1X Perm Buffer (Saponin-
based). The intracellular antibody cocktail listed in Table S1 were added into cell suspension for 1h. Cells were then washed in stain-
ing buffer and stained with DNA intercalator (Fluidigm) containing natural abundance Iridium (191Ir and 193Ir) prepared to a final
concentration of 125 nM in 2% paraformaldehyde. Cells were washed in staining buffer, with subsequent washes in Milli-Q water
(EMD Millipore) to remove buffer salts. Cells were resuspended in Milli-Q water with a 1:10 dilution of EQ Four Element Calibration
beads (Fluidigm) and filtered through a 35 mm nylon mesh filter cap (Corning, Falcon). Samples were analyzed on a Helios 2 CyTOF
Mass Cytometer (Fluidigm) equipped with a Super Sampler (Victorian Airship & Scientific Apparatus) at an event rate of 500 events/
second or less. Mass cytometry data files were normalized using the bead-based Normalizer (Finck et al. 2013) and analyzed using
Cytobank analysis software (https://www.cytobank.org/). The PhenoGraph clustering (Levine et al., 2015) and isomap dimensionality
reduction were done using R package cytofkit (Chen et al., 2016). Hierarchical clustering was used to determine two meta-clusters
based on the median of markers’ expression from each PhenoGraph clusters.
Flow Cytometry and Cell Sorting
All mouse FACS staining was performed in FACS buffer (D-PBS + 1% BSA + 0.1% sodium azide + 2mM EDTA) on ice. All human
FACS staining was performed in FACS buffer (D-PBS + 1% human serum + 0.1% sodium azide + 2mM EDTA) on ice. Cells
were filtered through sterile 70 mm cell strainers to obtain a single cell suspension (30,000 cells per ml for flow cytometry analysis,
0.5 - 23 107 per ml for sorting). Prior to surface staining, anti-CD16/32 (FITC) antibody (for mouse) or human Fc receptors blocking
reagent (MACS Miltenyi Biotec) was added for 15 min to stain and block the Fc receptors. Surface staining was performed for
30 minutes in a final volume of 500ul for FACS sorts and 100ul for regular flow cytometry. Cells were washed twice in at least
200ul FACS buffer before acquisition. Cells were sorted using a FACS Aria II and Aria-Fusion (BD biosciences) and conventional
flow cytometry using an LSRII or a LSR Fortessa (BD Biosciences). All flow cytometry was performed on live cells. Calculations of
percentages of CD45+ immune cells were based on live cells as determined by forward and side scatter and viability analysis. All
analyses and sorts were repeated at least 3 times, and purity of sorted fractions was checked visually and by FACS reanalysis of
the surface markers. Data were analyzed using Cytobank (https://www.cytobank.org/) and FlowJo (version 10.1r5).
Confocal Microscopy
Cells were FACS-sorted by using the flow cytometry panel shown in Figure S3D and resuspended in PBS. Following fixation in 4%
methanol-free formaldehyde in PBS for 10 min at room temperature, cells were washed with PBS and resuspended in 5% normal
donkey serum, 0.3% Triton X-100 in PBS for one hour. Cells were then incubated with a rabbit anti-Ki67 monoclonal antibody (clone
SP6, Abcam, 1:150) or negative control (normal rabbit IgG) in 1% bovine serum albumin and 0.3% Triton X-100 in PBS overnight
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647 (Cell Signaling, #4414, 1:500) and Hoechst (1:1000 of 10 mg/ml solution) for one hour at room temperature. After washing, cells
were adhered to poly-L-lysine coated #1.5H coverslips and embedded in Prolong Gold (Thermo Fisher). Samples were imagedwith a
Zeiss LSM780 and Leica SP8 confocal microscopes using a 63x/1.40 NA oil-immersion objectives. Images were processed with ZEN
or Leica HyVolution software and 3D reconstructions of DNA were created in Imaris software. The mean and integrated fluorescence
intensity (select the one you will show) of Ki-67 within the nuclear regions were calculated in Image-Pro Premier. To reduce Z-stretch-
ing confocal images were deconvolved with Huygens Essential. Analysis of the surface area, volume and sphericity was performed in
Imaris software.
Adoptive transfer
Recipient mice were housed in a barrier facility under pathogen-free conditions before and after adoptive transfer. NSG-SGM3 recip-
ient mice were maintained in sterile conditions at all times. CD45.1 recipient mice were fed with autoclaved acidified water with
antibiotics (trimethoprimsulfamethoxazole) for 3 days before the adoptive transfer. Sub-lethally irradiated recipient mice received
600 Rads. Donor BM cells were collected and FACS sorted as described in the flow cytometry section. Mouse and human progenitor
cells were sorted directly into sterile FBS and kept chilled during sorting. Cells thenwerewashed and resuspended in ice-cold D-PBS
for injection. 50,000 donor progenitors in 200 ul DPBS were delivered into each recipient mouse for Figures 3 and 4. 25,000 donor
progenitors in 200 ul DPBS were delivered into each recipient mouse for Figures 6 and 7. All adoptive transfer experiments were
achieved via tail vein injection. After the adoptive transfer, recipient mice were provided with autoclaved food and autoclaved acid-
ified water with antibiotics.
In vitro progenitor differentiation assay
Sorted progenitor cells were seeded into 6-well plates and cultured for 10 days with MethocultTM GF M3434 media (Stem Cell
Technologies) according to the manufacturer’s protocol. The numbers of wells containing proliferated colonies were counted
for -colony-forming assays.
Human T cell co-culture with NePs
To investigate the effects of NeP subsets on human autologous T cell activation, CD3+ T cells were negatively-selected from healthy
donor PBMCs (LJI NBDP) according to manufacturer’s instructions (Stem Cell Technologies). CD34+ hNeP, CD34- hNeP, and
mature neutrophils were FACS sorted from fresh human BM obtained from AllCells, Inc. (Alameda, CA). The sorted CD3+ T cells
were cultured with CD34+ hNeP, CD34- hNeP, and mature neutrophils at a 2:1 ratio, in the presence or absence of 2mg/mL plate-
bound anti-CD3 Ab (Biolegend) for 24 hr at 37C with 5% CO2. For polyclonal stimulation, purified CD3+ T cells were incubated
with anti-CD3,-CD28 Dynabeads (Invitrogen). To investigate CD69 activation, cells were collected and stained with anti-human
CD3, CD69, and a fixable live/dead viability dye at 24 hours post stimulation. 75,000 events were collected on the Fortessa (BD Bio-
sciences), and data was analyzed using FlowJo (v.10.3).
Single-cell RNA-seq. 30 end
Mouse Cluster#C cells were FACS-sorted using the flow cytometry panel shown in Figure S2C. Human hNeP were FACS-sorted by
using the flow cytometry panel shown in Figure 5A. Single cell RNA-Sequencing was performed using Chromium Single Cell 30 v2
Reagent Kits (10x Genomics) following the manufacturer’s protocol (Zheng et al., 2017). Briefly, after sort collection, cells were
resuspended in PBS at concentration ranging between 400 to 600 cells per ml. Between 5,000 to 10,000 cells were loaded for gel
bead-in-emulsion generation and barcoding. To increase barcode diversity, samples were split in 2 technical replicates for all down-
stream steps: Reverse transcription, cDNA amplification, fragmentation and library preparation. Final libraries with size ranging be-
tween 200 to 1000 bpwere size-selected using Ampure XP beads (BeckmanCoulter). Quality and quantity of samples was controlled
at multiple steps during the procedure by running small fraction (< 5%) of sample on BioAnalyzer (high sensitivity DNA chip, Agilent).
Libraries were sequenced on HiSeq2500 platform to obtain 26 (read1) x 100 (read2) paired-end reads.
Single cell RNA-Seq analysis
Using Cell Ranger v1.3.0 (10x genomics), reads were aligned on themm10 reference genome for mouse and hg19 reference genome
for human and unique molecular identifier gene expression profiles were generated for every single cell reaching standard
sequencing quality threshold (default parameters). On average we obtained data for 2868 cells for mouse samples and 518 cells
for human samples, and on average 46,477 reads per cell for mouse and 274,080 reads per cell for human. Only confidently mapped,
non-PCR duplicates with valid barcodes and UMIs were used to generate a gene-barcode matrix for further analysis. Counts were
normalized to get counts per million (CPM). Unbiased clustering of single cells was performed using Seurat (version 1.4) (Rizzo, 2016;
Satija et al., 2015). Principal Component Analysis (PCA) was performed using a set of top variable genes (ranging between 647 to
2142 genes) and then dimensionality reduction was performed using t-SNE algorithm with top 10 to 18 PCAs. For Figure 2A,
tSNE 2D plots were obtained applying Seurat scRNA-Seq analysis R Package (using 12 first PCA, and 810 most variable genes
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RNA-Seq
Cells were FACS-sorted by using the flow cytometry panel shown in Figure S3D. RNA-Seq was prepared on FACS sorted BM cells
using Universal Plus mRNA-Seq (Nugen) and sequenced on an Illumina 2500 instrument. Single-ended reads in FASTQ format were
mapped to mouse genome (mm10) using Rsubread (Liao et al., 2013) and overlapped with UCSC mm10 transcriptome annotation
from using FeatureCount R package(Liao et al., 2014). Gene expression level was then quantified as counts per million (CPM) using
edgeR(Robinson et al., 2010).
QUANTIFICATION AND STATISTICAL ANALYSIS
Data for all experiments were analyzed with Prism software (GraphPad). For Figure 4A and S5A, unpaired t tests were used to
compare the values in tumor groups to healthy groups. P value was calculated based on two-tailed comparison with 99%confidence
level. For Figure 4B and 7B, unpaired ordinary one-way ANOVA was used for multiple comparisons between experimental groups
and the control group. P value was calculated based on Dunnett’s test with 95% confidence level. No statistical methods were
used to predetermine sample size. No animal or sample was excluded from the analysis.Cell Reports 24, 2329–2341.e1–e8, August 28, 2018 e8
